In this study, a method for synthesizing ultra-small populations of biocompatible nanoparticles was described, as well as several in vitro methods by which to assess their cellular interactions.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
In this study, a method for synthesizing ultra-small populations of biocompatible nanoparticles was described, as well as several in vitro methods by which to assess their cellular interactions.
Nanoparticle-based delivery vehicles have shown great promise for intracellular targeting applications, providing a mechanism to specifically alter cellular signaling and gene expression. In a previous investigation, the synthesis of ultra-small solid lipid nanoparticles (SLNs) for topical drug delivery and biomarker detection applications was demonstrated. SLNs are a well-studied example of a nanoparticle delivery system that has emerged as a promising drug delivery vehicle. In this study, SLNs were loaded with a fluorescent dye and used as a model to investigate particle-cell interactions. The phase inversion temperature (PIT) method was used for the synthesis of ultra-small populations of biocompatible nanoparticles. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylphenyltetrazolium bromide (MTT) assay was utilized in order to establish appropriate dosing levels prior to the nanoparticle-cell interaction studies. Furthermore, primary human dermal fibroblasts and mouse dendritic cells were exposed to dye-loaded SLN over time and the interactions with respect to toxicity and particle uptake were characterized using fluorescence microscopy and flow cytometry. This study demonstrated that ultra-small SLNs, as a nanoparticle delivery system, are suitable for intracellular targeting of different cell types.
Nanoparticle-based delivery vehicles have shown great promise for intracellular targeting applications, providing a mechanism to specifically alter cellular signaling and gene expression. These vehicles can be loaded with drugs, proteins, and nucleic acids designed to impact cellular responses and achieve a desired effect in target tissues. Many types of nanocarriers have been explored for therapeutic and diagnostic benefit including lipids, polymers, silicon, and magnetic materials. These systems are attractive due to their potential for localized drug delivery, increased therapeutic concentration in target tissues, and reduction of systemic toxicity.
Access restricted. Please log in or start a trial to view this content.
1. Processing of SLNs
Access restricted. Please log in or start a trial to view this content.
The PIT method was used to synthesize the SLNs and the phase inversion temperature was determined utilizing a water bath. The samples were slowly heated and gently agitated until the solution appeared clear. The phase inversion temperature for the SLNs made using heneicosane lipid is 45 °C. Table 1 summarizes the particle size, polydispersity, melting point and latent heat of melting for the SLNs. The SLNs synthesized using the processing conditions described above resulted in control SLNs and NiR-loaded.......
Access restricted. Please log in or start a trial to view this content.
In this study, the synthesis of SLNs and their applicability for intracellular targeting applications were explored. These biocompatible nanoparticles have shown promise as delivery vehicles for multiple applications including drug delivery, gene silencing, and vaccine technologies 25-30. Ultra-small SLNs were synthesized using a facile process, and their interactions with primary skin cells and primary immune cells were explored. SLNs were designed to include encapsulation of a fluorescent dye (NiR), which se.......
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
Research reported in this publication was supported by The Johns Hopkins Applied Physics Laboratory’s Research and Exploratory Development Department, Office of Technology Transfer, and Stuart S. Janney Fellowship Program, in addition to the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R21HL127355.
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| Nile Red (NiR) | Sigma | 19123 | BioReagent, suitable for fluorescence, ≥98.0% |
| Heneicosane | Aldrich | 286052 | 98% |
| Brij O10 | Sigma | P6136 | Brij 97, C18-1E10, Polyoxyethylene (10) oleyl ether |
| Water | Sigma | W3500 | Sterile-filtered, BioReagent, suitable for cell culture |
| Syringe Filter 0.2 µm Supor Membrane Low Protein Binding | Life Sciences | PN4612 | Non-Pyrogenic |
| Nanotrac Ultra | Microtrac | serial number U1985IS | Instrument |
| Differential Scanning Calorimeter | Mettlet-Toledo | Instument | |
| Primary human fibroblasts | Life Technologies | C-004-5C | Neonatal (HDFn) |
| Medium 106 | Life Technologies | M-106-500 | A sterile, liquid medium for the culture of human dermal fibroblasts. |
| Low Serum Growth Supplement Kit (LSGS Kit) | Life Technologies | S-003-K | All the components of complete LSGS |
| MTT Cell Proliferation Assay Kit | Trevigen | 4890-025-K | Sensitive kit for the measurement of cell proliferation based upon the reduction of the tetrazolium salt, 3-[4,5-dimethylthiazol-2- yl]-2,5-diphenyl-tetrazolium bromide (MTT) |
| Safire2 microplate reader | Tecan | ---- | Instrument |
| Phosphate buffered saline | Sigma | P5493 | For molecular biology |
| Recombinant murine GM-CSF | Peprotech | 315-03 | >97%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
| Recombinant murine IL-4 | Peprotech | 214-14 | >97%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
Access restricted. Please log in or start a trial to view this content.